Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SAN FRANCISCO, Nov. 28, 2016 -- Hagens Berman Sobol Shapiro LLP reminds investors in Cempra Inc. (NASDAQ:CEMP) to the securities fraud class action filed against the Company and the January 3, 2017 lead plaintiff deadline.
If you purchased or otherwise acquired securities of Cempra between May 1, 2016 and November 1, 2016 and suffered over $50,000 in losses, contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/CEMP
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
Cempra allegedly failed to disclose to investors that its drug, solithromycin, created significant health risks to users.
On November 2, 2016 the Food and Drug Administration reported on its website that solithromycin may cause a serious rise in liver enzymes and result in hepatotoxicity. Disclosure of the FDA’s report drove the price of Cempra shares down approximately 60% to close at $7.30 per share that day.
On November 3, 2016 Benzinga quoted a stock analyst who stated: “[w]e had previously argued liver enzyme elevations alone would be a navigable subject matter – but the revelation of a previously-undisclosed instance of definitive solithromycin mediated drug-induced liver injury…now fundamentally challenges this hypothesis.”
“We’re evaluating the FDA’s material and the results of the FDA’s advisory panel meeting today in the context of the Company’s and management’s public statements about solithromycin,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Cempra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
